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Activating JAK2mutants cause hematological malignancies. Current clinical type I JAK2 inhibitors effectively
relieve symptoms but fail to resolve the disease. In this issue of Cancer Cell, two articles by Wu and col-
leagues and Meyer and colleagues characterize a type II JAK2 inhibitor that is effective in preclinical models
of JAK2-dependent myeloproliferative neoplasms and B cell acute lymphoblastic leukemia.The Janus tyrosine kinases (JAK1–3,
TYK2) mediate signaling by various cyto-
kine and hormone receptors. JAK2 asso-
ciates with cytokine receptors involved
in myelopoiesis, such as the erythropoi-
etin and thrombopoietin receptors, and
regulates proliferation, apoptosis, and
differentiation through STAT, Ras-MAPK,
and phosphoinositide 3-kinase pathways.
A decade ago, JAK2was drawn into the
spotlight of hematological malignancies
when an activating mutation (V617F) in its
pseudokinase domain was identified as a
major cause (80%)of themyeloprolifera-
tive neoplasms (MPNs) polycythemia vera
(PV), essential thrombocythemia (ET), and
primary myelofibrosis (PMF). Numerous
other activating JAK2mutations have sub-
sequently been found in MPNs and in
different forms of leukemia (Vainchenker
and Constantinescu, 2013). Most of these
mutations localize in or are adjacent to the
pseudokinase domain, with rare muta-
tions found in the tyrosine kinase domain.
In B cell acute lymphoblastic leukemia
(B-ALL), mutations in both the pseudoki-
nase domain (R683G/S) and the kinase
domain (D873R, P933R) have been linked
to the disease. Recent structural data on
JAKsshowhow thepseudokinasedomain
interacts with the kinase domain to main-
tain low basal activity (Lupardus et al.,
2014, Shan et al., 2014), and most of the
pathogenicmutations localize in this inter-
face and are expected to destabilize the
inhibitory interaction and lead to constitu-
tive kinase activation (Silvennoinen and
Hubbard, 2015).
Realization of the central role for JAK2 in
MPNs led to an exceptionally rapid devel-opment of JAK2 inhibitors and their entry
into clinical use (Mascarenhas et al.,
2014). The JAK2/1 inhibitor ruxolitinib is
FDA-approved for myelofibrosis and hy-
droxyurea-resistant PV, and several other
JAK inhibitors are in clinical trials. All the
currently developed JAK2 inhibitors are
type I inhibitors, which bind in the ATP
binding pocket of the kinase domain in
its active configuration. Because the pre-
dominant MPN mutations localize in the
pseudokinase domain, these compounds
inhibit both wild-type JAK2 and constitu-
tively active pathogenic forms. The speci-
ficity of the compounds for JAK2 versus
off-target kinases varies, resulting in
slightly different clinical responses and
adverse effects. In general, all inhibitors
lead to improvement in systemic symp-
toms and splenomegaly but have only a
modest effect on themutant allele burden.
It has been suggested that the majority of
the clinical effects are not caused by inhi-
bition of JAK2 but are due to off-target
effects (mainly JAK1) and suppression of
inflammatory responses. Thus, it has
become uncertain whether JAK2 is actu-
ally a relevant target in MPNs. However,
the poor responses on mutant allele
burden and the lack of secondary muta-
tions causing resistance to JAK inhibitors
suggest that insufficient JAK2 inhibition
and survival of the pathogenic cells under-
lie the limited therapeutic efficiency of the
drugs. Collectively, these findings warrant
development of better JAK inhibitors.
In this issue ofCancer Cell, two accom-
panying articles characterize the type II
JAK2 inhibitor NVP-CHZ868 in preclinical
MPN (Meyer et al., 2015) and B-ALL (WuCancer Cet al., 2015) models. A type II kinase
inhibitor, like type I, displaces ATP in the
ATP binding pocket (and thus abrogates
phosphoryl transfer) but binds to an inac-
tive rather than active configuration of the
kinase activation loop (Figure 1). The au-
thors have previously described JAK2
inhibitor resistance in MPN cells, termed
persistency, following long-term treatment
with type I inhibitors (Koppikar et al., 2012).
Interestingly, a type II BCR-ABL inhibitor,
NVP-BBT594, was shown to inhibit both
normal and persistent JAK2 signaling (An-
draoset al., 2012). Thesefindings led to the
development of NVP-CHZ868. CHZ868
has a rather narrow specificity spectrum,
exhibiting activity against <30 kinases,
which include JAK2, TYK2, and some re-
ceptor-tyrosine kinases, but not JAK1 or
JAK3. CHZ868 was found to be compara-
ble, or slightlymore potent, than ruxolitinib
in inhibiting proliferation of cells with wild-
type JAK2 but was significantly more
potent in inhibiting and inducing apoptosis
in cells expressing JAK2 V617F, MPL
W515L, or CRLF2-JAK2 R683G.
The potency of CHZ868 was analyzed
in severalMPN andB-ALLmousemodels,
and the results were quite striking. In
both JAK2 V617F-induced PV and MPL
W515L-induced myelofibrosis, CHZ868
treatment reverted the pathological hema-
tological parameters. Most significantly,
the mutant allele burden was reduced
and myelofibrosis attenuated. The re-
sponses were surprisingly rapid, and the
treatment induced apoptosis of mutant
cells.Given thepotency of JAK2 inhibition,
the effect of CHZ868 treatment on normal
hematopoiesis was unexpectedly small.ell 28, July 13, 2015 ª2015 Elsevier Inc. 1
Figure 1. Comparison of a Type I versus Type II JAK2 Inhibitor
(A) Ruxolitinib (type I inhibitor), shown in ball-and-stick representation and with a semi-transparent
surface, is modeled in the ATP binding pocket of the kinase domain of JAK2 based on the co-crystal struc-
ture of ruxolitinib with Src tyrosine kinase (PDB code 4U5J). Carbon atoms of ruxolitinib are colored yellow
and nitrogen atoms are colored blue. The JAK2 kinase domain is colored orange, with the P loop colored
blue; the C helix is colored pink, and the activation loop is colored green. Phe995 in the activation loop is in
the ‘‘DFG-in,’’ active configuration.
(B) Co-crystal structure of BBT594 (type II inhibitor) and the JAK2 kinase domain (PDB code 3UGC).
BBT594 is represented similarly to ruxolitinib in (A), with carbon atoms colored cyan, oxygen atoms
red, nitrogen atoms blue, and fluorine atoms purple. The JAK2 kinase domain is colored as in (A).
Phe995 in the activation loop is in the ‘‘DFG-out,’’ inactive configuration, and the majority of the loop is
disordered (represented by the green spheres). Also shown is the position of Leu884, the site of the recur-
rent mutation L884P, which renders JAK2 refractory to the suppressive effects of CHZ868.
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ments harbor JAK2 Arg683 mutations
in approximately 50% of cases (Mullighan
et al., 2009), and the leukemic cells are
refractory to type I JAK inhibitors and
currently lack effective therapy. Wu et al.
(2015) tested the effect of CHZ868 in
various B-ALL models and found efficient
inhibition of JAK2-dependent leukemic
cellswith similar potency aswasobserved
in MPNs. In a cell line with rearranged
CRLF2 and the JAK2 mutation I682F,
CHZ868 was 40-fold more potent than
type I inhibitors, and, in patient-derived
cells with rearranged CRLF2, CHZ868
treatment primed JAK2-dependent cells
for apoptosis and downregulated MYC
and E2F1 gene sets in xenografts. 6 days
of CHZ868 treatment showed reduced
splenomegaly and improved survival
compared to vehicle-treated mice.
The authors then screened for synergy
with several currently used chemother-
apies, and the most notable effect was
observed in combinationwith dexametha-
sone. CHZ868 or dexamethasone alone
had rather similar effects on proliferation
and apoptosis, but the combination had
synergistic effects only in CRLF2-rear-
ranged cells. The synergistic effect was
also observed in the EmCRLF2/R683G
mouse model, where the combination
reduced splenomegaly and increased
overall survival. The combination also ap-
peared to enhance the safety profile,2 Cancer Cell 28, July 13, 2015 ª2015 Elsevibecause it reduced apoptosis of normal
cells compared to CHZ868 treatment
alone. The underlying molecular mech-
anism for the synergistic effect is not
known but may involve regulators of the
apoptosis pathway.
These two articles provide compelling
evidence for the efficacy of type II JAK2
inhibitors in MPN and B-ALL. The potency
of CHZ868 in persistent cells and its selec-
tivity for pathogenic JAK2 are intriguing
and raise important mechanistic ques-
tions. For example, it is not altogether clear
why a type II JAK2 inhibitor would be less
susceptible to persistence than a type I in-
hibitor. Persistence occurs with all tested
type I inhibitors and involves heterodimeri-
zation of JAK2, particularly with JAK1,
and constitutive phosphorylation of the
JAK2 activation loop (Koppikar et al.,
2012). Moreover, a type II inhibitor would
not be effective against JAK2 molecules
that become activated (phosphorylated),
whereas a type I inhibitor specifically tar-
gets activated JAK2. Furthermore, both
type I and II inhibitors targeting the JAK2ki-
nase domain would be expected to inhibit
both wild-type JAK2 and hyperactive mu-
tants such as V617F. That is, there is no
inherent selectivity advantage (mutant
versus wild-type) for a type II JAK2 inhibi-
tor, although they tend to provide greater
kinase specificity.
The authors did not detect resis-
tance against CHZ868, but amutagenesiser Inc.screen performed with JAK2 R683G-
expressing cells identified one recurrent
mutation (L884P) that abrogated the sup-
pressive effects of CHZ868. L884P has
been identified in B-ALL cases and was
shown tobeanactivatingmutation incells.
Modeling based on the crystal structure of
the JAK2 kinase domain in complex with
type II inhibitor BBT594 suggested that
L884P destabilizes the P loop andC-helix,
favoring the active DFG-in conformation
(Wu et al., 2015) (Figure 1). Structural
data are needed to reveal how L884P ren-
ders R683G-mutated (but not V617F-
mutated) JAK2 resistant to CHZ868, but
the obvious implication for future thera-
peutic approaches is the need for genetic
analysis.
Although further studies are needed
to directly compare type I and the new
type II compounds in animal models,
define the mechanism of inhibition, and
evaluate the possible off-target effects, it
is clear that the type II inhibitors provide a
very promising entry to the JAKinibs field.REFERENCES
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